- Telehealth visits
Geraldina Lionetti, MD
Pediatric Rheumatology- Telehealth visits
Geraldina Lionetti, MD
Pediatric Rheumatology- Telehealth visits
On this page
About me
Dr. Geraldina Lionetti is a pediatric rheumatologist who focuses on improving outcomes for children with rheumatic diseases through comprehensive evaluations and individualized treatment plans. Her goal is to help her patients enter adulthood unhindered by their disease.
In addition to caring for patients on site at UCSF, Lionetti goes to see patients throughout Northern California who are unable to travel. She also runs outreach clinics to ensure adequate access to care and is developing a telemedicine program to improve patient and provider access to specialized care.
As an educator, Lionetti strives to give pediatric residents a strong foundation for care of children with rheumatic diseases.
Lionetti received her medical degree from Drexel University College of Medicine and completed her residency at Children's Hospital Los Angeles. She completed a fellowship in pediatric rheumatology at Lucile Packard Children's Hospital Stanford.
Education & training
Board certification
- Pediatric Rheumatology, American Board of Pediatrics
Fellowship
- Pediatric Rheumatology, Lucile Salter Packard Childrens Hospital -Stanford
Residency
- Pediatrics, Childrens Hospital - Los Angeles GME
Internship
- Pediatrics, Childrens Hospital - Los Angeles GME
Degree
- MD, Drexel University College of Medicine
Academic Title
- Health Sciences Clinical Professor
My expertise
Specialties
Locations
My research
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.